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The quality of life and the occurrence 
of dysphagia in patients with head 
and neck cancer following combined 
oncological treatment
ABSTRACT
Introduction. The localisation of head and neck carcinomas influences the functions of speech, breathing, 
and swallowing, which, in turn, directly affect the patient’s quality of life. The poor prognosis associated 
with tumours of this type indicates that aggressive combined therapy protocols, including surgery, chemo-
therapy, and radiotherapy, should be implemented. Such treatments commonly cause acute toxicity and 
short- and long-term swallowing complications. Therefore, even though they can contribute significantly to 
survivorship, these treatments reduce the quality of life. The aim of this study was to analyse the influence 
of applied combined oncological treatments on the occurrence of dysphagia in patients with head and 
neck cancer and on their quality of life. 
Methods. A group of 135 patients with head and neck carcinomas treated with combined protocol (surgery, 
chemotherapy, and radiotherapy) in the Lukaszczyk Oncological Centre in Bydgoszcz between 2010 and 
2014 was analysed. The quality of life and subjective evaluation of the swallowing function was assessed 
using the MDADI (M.D. Anderson Dysphagia Inventory). 
Results. A statistically significantly worse subjective evaluation of the quality of life was observed in the 
patients with dysphagia, who had undergone surgery with radiotherapy, compared to those who had not 
had surgery (p = 0.03). A statistically significantly worse subjective quality of life evaluation was found in 
patients who had the most locally advanced tumours (T4) (p = 0.04) as well as the highest stages of the 
disease (S3 and S4) (p = 0.04). A statistically significantly worse subjective quality of life with dysphagia 
was also seen in patients who had chemoradiotherapy in comparison to those who had radiotherapy 
alone (p = 0.01). A statistically significantly worse subjective quality of life with dysphagia was observed 
in the patients whose tumours were localised in the oral part of the pharynx and larynx compared to those 
patients with other tumour localisations (p = 0.02). A statistically significantly worse subjective quality of 
life with dysphagia was identified in the patients who had a higher dose of radiation (exceeding 45 Gy) 
in the upper oesophageal sphincter compared to those patients who had a lower dose (below 45 Gy) in 
the UES (p = 0.01). 
Conclusions. In patients with dysphagia, surgical treatment negatively impacts their subjective quality 
of life. Moreover, the pattern of radiation therapy affects the quality of life in patients with dysphagia. 
A radiation therapy plan that spares the upper oesophageal sphincter by using a dose of less than 45 Gy 
may prevent dysphagia. Dysphagia is also associated with tumour localization, tumour stage, and local 
advancement of the disease.
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Introduction
Malignant head and neck tumours are localised 
within the mucosa of the upper respiratory and gas-
trointestinal tract (oral cavity, pharynx, larynx, nasal 
cavity, salivary glands, and paranasal sinuses) and are 
related to similar diagnostic and therapeutic problems, 
although these differ along with the natural clinical 
course of the disease and prognosis [1]. This localisa-
tion of tumours significantly affects the most important 
life functions of speech, breathing, and swallowing, 
which, in turn, negatively impact the quality of life of 
the patient. These functions are influenced, on the one 
hand, by the tumour infiltrating the organs, but, on 
the other hand, are compromised by the aggressive 
oncological treatment. Despite modern methods of 
combined treatment, cases of head and neck cancers 
are characterised by a poor prognosis; the five-year 
survival rate is 50% [2]. Aggressive, combined treat-
ment (radiochemotherapy and surgery) is therefore 
typically used to improve the therapeutic effect. This 
treatment, however, is characterised by high toxicity 
and increases the risk of early and late post-radiation 
effects, negatively affecting the patient’s quality of life 
[3]. Dysphagia is present at the moment of diagnosis 
in 2/3 of patients suffering from head and neck cancer. 
In 1/3 of the patients with dysphagia, aspiration is ob-
served and is complicated by aspiration pneumonia, 
which, according to various authors, carries a high 
mortality rate ranging from 20–60% [3]. The aim of the 
present analysis has been to evaluate the influence 
of the applied therapy on the quality of life of patients 
with head and neck cancer and the occurrence of 
dysphagia. 
Materials and methods
Patients
We selected 135 patients suffering from head and 
neck cancer, who were treated with combined thera-
py (surgery, chemotherapy, and radiotherapy) in the 
Oncological Centre in Bydgoszcz between 2010 and 
2014, in order to evaluate their quality of life and dys-
phagia. Table 1 presents the clinical characteristics 
of the patients. Table 2 presents the morphological 
Table 1. Characteristics of patients 
Women Men
Av. Age (years) 58.13 58.54
Smoking 27% 39%
Alcohol 5% 17%
Table 2. Morphological characteristics of tumours
Number of patients %
T1 15 11%
T2 48 35%
T3 48 35%
T4 22 16%
TX 2 1%
N+ 76 57%
N1 14 10%
N2a 9 6%
N2b 29 21%
N2c 22 16%
N3 2 1%
N– 59 43%
M+ 0 0
M- 135 100%
S I 13 10%
SII 26 19%
SIII 30 23%
SIVa 58 43%
SIVb 7 5%
SIVc 1 0.01%
Squamous cell carcinoma 135 100%
T — tumour size; N — the presence of lymph node metastases;  
M — the presence of metastases; S — stage of disease (SI–SIVc)
Table 3. Tumour localisation 
Tumour localisation Number of patients  
(n = 135)
Oral cavity 21
Oropharynx 38
Hypopharynx 12
Larynx 49
Tumours infiltrating more than one 
organ (oral cavity and oropharynx. 
hypopharynx and larynx)
15
characteristics of the tumours. Table 3 presents the 
localisation of the tumours, and Table 4 shows the type 
of treatment applied. 
A subjective evaluation of the quality of life and dys-
phagia in patients following the combined oncological 
treatment was performed using the Polish translation 
of the MDADI (M.D. Anderson Dysphagia Inventory) 
[4]. The MDADI questionnaire includes four groups of 
questions characterising the factors influencing patient 
quality of life:
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Table 4. Characteristics of the treatment
Treatment Number of patients (n = 135)
Planning radiotherapy with PET-CT 51 (38%)
Radiotherapy 16 (12%)
Chemo-radiotherapy 31 (23%)
Radiotherapy/chemo-radiotherapy+ surgical treatment 88(65%)
Table 5. Subjective evaluation of dysphagia in patients with respect to the applied treatment
Questions Surgical treatment No surgical treatment
1 — global assessment of swallowing difficulty NS NS
2 — emotional disorders correlated with dysphagia p = 0.0376 NS
3 — family and social dysfunction related to dysphagia p = 0.3604 NS
4 — functional effects of dysphagia NS NS
NS — no statistical significance
 — the first group of questions: the global assessment 
of swallowing difficulty (question 1);
 — the second group of questions concerns the emo-
tional disorders correlated with dysphagia (ques-
tions: 2, 5, 6, 12, 18);
 — the third group of questions concerns family and 
social dysfunction related to dysphagia (questions: 
3, 9, 14, 15, 20);
 — the fourth group of questions concerns the func-
tional effects of dysphagia (questions: 4, 7, 10, 11, 
13, 16, 17, 19).
Out of five possible answer choices, only one could 
be selected: 1- strongly agree, 2 -agree, 3 — no opinion, 
4 — disagree, 5 —  strongly disagree. The items were 
scored, and the mean score was multiplied by 20 to 
obtain a score with the range from 0 (extremely low 
functioning) to 100 (high functioning) [5, 6].
Approval for the research program was granted 
by the Ethical Committee of the Nicolaus Copernicus 
University in Torun, Medical College in Bydgoszcz 
(KB365/2013). All the patients included in the program 
agreed to participate in the analysis. 
Statistical analysis
The statistical evaluation was performed using the 
Statistica 8.0 program (StatSoft, Inc., USA). 
The statistical significance between the groups was 
determined by the Kruskal–Wallis test, one-way analysis 
of variance by ranks. The Mann–Whitney U test was 
then used as applicable. All statistical analyses were 
carried out with Statistica 8.0 software (StatSoft Inc, 
Tulsa, OK, USA). A p value < 0.05 was considered to 
be of statistical significance [7–11].
Results
A statistically significantly worse subjective evalua-
tion of the quality of life, including emotional disorders 
(group 2) (p = 0.03) and family and social dysfunction 
(group 3) (p = 0.03), was observed in the patients who 
underwent surgical therapy combined with radiothera-
py, compared to patients who underwent radiotherapy 
without surgery. Table 5 presents the results.
A statistically significantly worse subjective evalua-
tion of the quality of life (global assessment of swallow-
ing difficulty) (group 1) was observed in the patients with 
the greatest local tumour size (T4) compared to patients 
with smaller tumour size (T1, T2, and T3) (p = 0.04). 
Similarly, a statistically significantly worse subjective 
quality of life with functional disorders (group 4) was 
observed in the patients with the greatest tumour size 
(T4) (p = 0.04). Table 6 presents the results.
A statistically significantly worse subjective eval-
uation of the quality of life with global assessment of 
swallowing difficulty (group 1) was observed in the pa-
tients with higher stages of the disease (stage 3 and 4, 
p = 0.04). Table 7 presents the results. 
A statistically significantly worse subjective quality 
of life with functional disorders (group 4) was observed 
in the patients who underwent chemoradiotherapy 
compared to those patients who underwent only radio-
therapy (p = 0.01). Table 8 presents the results. 
A statistically significantly worse subjective eval-
uation of the quality of life with functional disorders 
(group 4) was observed in patients whose tumour 
localisations included the oropharynx (p = 0.027) and 
larynx (p = 0.02) when compared to other tumour lo-
calisations. Table 9 presents the results. 
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Table 6. Subjective evaluation of swallowing difficulty with respect to tumour size
Questions group T1 T2 T3 T4
1 NS NS NS p = 0.0480
2 NS NS NS NS
3 NS NS NS NS
4 NS NS NS 0.0477
NS — no statistical significance; questions group: group 1 — the global assessment of swallowing difficulty; group 2 — emotional disorders cor-
related with dysphagia; group 3 — family and social dysfunction related to dysphagia; group 4 — functional effects of dysphagia
Table 7. Subjective assessment of dysphagia with respect to the tumour stage
Group of questions Stage 1 Stage 2 Stage 3 Stage 4
1 NS NS p = 0.040 p = 0.0478
2 NS NS NS NS
3 NS NS NS NS
4 NS NS NS NS
NS — no statistical significance; questions group: group 1 — the global assessment of swallowing difficulty; group 2 — emotional disorders cor-
related with dysphagia; group 3 — family and social dysfunction related to dysphagia; group 4 — functional effects of dysphagia
Table 8. Subjective assessment of dysphagia with respect to the applied treatment
Group of questions Patients after radiotherapy Patients after chemoradiotherapy
1 NS NS
2 NS NS
3 NS NS
4 NS p = 0.0128
NS — no statistical significance; questions group: group 1 — the global assessment of swallowing difficulty; group 2 — emotional disorders cor-
related with dysphagia; group 3 — family and social dysfunction related to dysphagia; group 4 — functional effects of dysphagia
Table 9. Subjective evaluation of dysphagia with respect to tumour localisation
Group of questions Tumour localisation  
— oropharynx
Tumour localisation  
— hypopharynx
Tumour localisation  
— larynx
Other localisation
1 NS NS NS NS
2 NS NS NS NS
3 NS NS NS NS
4 p = 0.0277 NS p = 0.0218 NS
NS — no statistical significance; questions group: group 1 — the global assessment of swallowing difficulty; group 2 — emotional disorders cor-
related with dysphagia; group 3 — family and social dysfunction related to dysphagia; group 4 — functional effects of dysphagia
A statistically significantly worse subjective evalua-
tion of the quality of life with global assessment of swal-
lowing difficulty (group 1) was observed in the patients 
in whom the median dose within the upper pharyngeal 
constrictor (identified as a critical structure) exceeded 
45 Gy compared to those patients in whom the dose 
was lower (p = 0.01). Table 10 presents the results. 
No statistically significant differences were identified 
in the analysed groups of patients in relation to the sex, 
age, the presence of lymph node metastases (N+), tu-
mour grading, and local tumour progression. Table 11 
presents the results. 
Discussion
In the present study, a statistically significantly worse 
individual evaluation of the quality of life was observed 
in the global assessment of swallowing difficulty and 
family and social dysfunction in the patients with the 
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Table 10. Subjective evaluation of dysphagia with respect to the dose of radiotherapy applied to pharyngeal 
constrictors
Group of questions Radiotherapy dose in pharyngeal 
constrictors exceeding 45 Gy
Radiotherapy dose in pharyngeal 
constrictors not exceeding 45 Gy
1 p = 0.0118 NS
2 NS NS
3 NS NS
4 NS NS
NS — no statistical significance; questions group: group 1 — the global assessment of swallowing difficulty; group 2 — emotional disorders cor-
related with dysphagia; group 3 — family and social dysfunction related to dysphagia; group 4 — functional effects of dysphagia
Table 11. Subjective assessment of dysphagia with respect to sex, age, the presence of lymph node metastases, 
tumour grade, and local tumour progression
Group of 
questions
Age Sex N+ G1 G2 G3 Local tumour 
progression
1 NS NS NS NS NS NS NS
2 NS NS NS NS NS NS NS
3 NS NS NS NS NS NS NS
4 NS NS NS NS NS NS NS
NS — no statistical significance; questions group: group 1 — the global assessment of swallowing difficulty; group 2 — emotional disorders cor-
related with dysphagia; group 3 — family and social dysfunction related to dysphagia; group 4 — functional effects of dysphagia
greatest tumour size (T4). A similarly statistically signifi-
cantly worse individual evaluation of global assessment 
of swallowing difficulty was observed in the patients 
whose tumours were in the highest stages (stages 
3 and 4). The obtained results remain in accord with 
the observations of other authors who confirmed that 
local tumour advancement affects the primary function 
of the organ and the adjacent tissues, which disturbs 
the swallowing process before, during, and after the 
completion of treatment [12]. Eisbruch et al. stated that 
the most important factors predicting severe dysphagia 
include tumour size (T3/T4), extra glottic tumour locali-
sation, and hyperfractionation of the radiation dose [13]. 
In the present study, a statistically significantly worse 
individual evaluation of the quality of life with functional 
effects of dysphagia (group 4) was found in patients 
who had tumours localised in the oropharynx and larynx 
compared to other localisations. Strek et al. had similar 
observations [4–5]. The severest dysphagia was iden-
tified in patients in whom the tumour was localised in 
the oral cavity, oropharynx, and larynx with involvement 
of the epiglottis. These tumour localisations constitute 
the worst prognostic factors in cases of dysphagia. 
Eisbruch et.al. described the basic structures for the 
process of swallowing and aspiration, destruction of 
which during the treatment procedures leads to dyspha-
gia. These structures include pharyngeal constrictors, 
glottis, and supraglottic larynx [13]. It would seem, 
therefore, that the most important predictive factor of 
dysphagia is the tumour localisation. Our results confirm 
this observation. 
A statistically significantly worse individual quality 
of life with emotional disorders and family and social 
dysfunction was observed in the patients who under-
went surgical treatment with radiotherapy compared 
to those patients who underwent radiotherapy alone. 
The surgical treatment itself affects the function of the 
resected organ; additionally, the post-surgical wound 
healing process induces fibrosis, which also compro-
mises proper organ functions. Additional treatment, 
such as radiotherapy and chemotherapy, escalates the 
swallowing problems by inducing the acute and late ra-
diation reaction stimulating fibrosis in the subcutaneous 
tissue and muscles of the irradiated area. In our study, 
significant deterioration of the quality of life in these 
patients was observed. The results obtained by using 
the MDADI questionnaire for all patients undergoing 
surgical treatment, regardless of the type of surgery, 
are in accord with other study results demonstrating 
a diminished quality of life [4, 5]. 
A statistically significantly worse individual quality of 
life in the functional effects of dysphagia (group 4) was 
observed in patients who had radiochemotherapy com-
pared to patients who underwent radiotherapy alone. Al-
though radiochemotherapy increases the local tumour 
control and improves the survival rate while preserving 
the organ, it is characterised by higher toxicity than 
radiotherapy [14, 15]. The incidence of complications 
following treatment in patients in WHO stages 3 and 4 in-
creases from 14% following radiotherapy alone to 43% 
following chemoradiotherapy [16]. The most common 
chemotherapies applied in patients with head and neck 
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cancer are antimetabolites, taxanes, platinum-based 
chemotherapy, and carboplatin. Antimetabolites such 
as methotrexate and 5-fluorouracil seem to have the 
strongest impact on the development of mucositis; 
taxanes are commonly related to allergic reactions and 
peripheral neurotoxicity, while platinum-based antineo-
plastic chemotherapy induces a strong haematological 
toxicity [16, 17]. Simultaneous chemotherapy was the 
strongest factor correlating with an acute morbidity rate 
in various studies [16–18]. The combination of chemo-
therapy with radiotherapy reduces the critical dose of 
radiotherapy for the swallowing process, which seems 
to be related to the acute radiotherapy reaction and its 
consequences for the pharyngeal and laryngeal muco-
sa [19]. In a randomised trial RTOG 91-11 the strong mu-
cositis of the oral cavity and dysphagia increased with 
the chemotherapy doses compared to the radiotherapy 
doses, from 24% and 19% (radiotherapy alone) to 43% 
and 35% (simultaneous chemoradiotherapy) [20]. 
Despite this, the survival rate was significantly better in 
patients following chemoradiotherapy (72 months) than 
in patients following radiotherapy alone (32 months). 
The Kaplan-Meyer analysis puts the overall five-year 
survival rate at 40% for the group of patients following 
radiotherapy and at 53% for the patients following 
chemoradiotherapy [21].
In the present study, a statistically significantly 
worse global assessment of swallowing difficulty (group 
1) was identified in patients for whom the maximum 
dose of radiotherapy in the pharyngeal constrictors 
exceeded 60Gy in comparison to patients for whom 
the dose did not exceed 45 Gy (in these patients the 
upper pharyngeal sphincter was considered a critical 
structure) (p = 0.049). Levendag et al. have noticed 
a correlation between dysphagia and increasing the 
dose of radiotherapy applied in the upper and medial 
pharyngeal constrictors: 19% greater likelihood for ev-
ery 10Gy once the 55Gy dose is exceeded. The volume 
of the structures responsible for swallowing was the 
prognostic factor [22]. It was therefore confirmed that 
the core element that determines the quality of life in 
patients with dysphagia is the type of treatment applied, 
including the type of surgery, the use of chemotherapy, 
the general dose of radiotherapy, and the dose applied 
within the pharyngeal constrictors. In the TransTasman 
Radiation Oncology Group (TROG) 91.01 study the 
volume of irradiated pharyngeal tissues (including the 
mucosa and sphincter muscles) correlated with the risk 
of enteral nutrition [23]. Deantonio et al. demonstrated 
that the medium dose for the upper and medial pha-
ryngeal constrictors statistically significantly correlated 
with the degree of dysphagia [24]. Larson has likewise 
observed correlations between the dose of radiothera-
py and complications following radiotherapy [25]. The 
evaluation of severe dysphagia as a late complication 
of radiotherapy in patients surviving longer than five 
years was performed by Hutcheson et al. The total 
dose of radiotherapy impacted the occurrence of late 
dysphagia; it was observed more frequently in patients 
with a total dose of 70 Gy or higher [26]. Many authors 
have observed positive effects from proactive swallow-
ing therapy, which were observed not just following the 
treatment but also 3–6 months after the completion of 
chemoradiotherapy and 9–12 months after treatment 
[27–32]. 
Conclusions
The type of oncological treatment (surgery, che-
motherapy, and the dose of radiotherapy) affects the 
process of swallowing and can influence the occurrence 
of dysphagia. The dose of radiotherapy in the upper 
pharyngeal constrictors determines the type and sever-
ity of the swallowing problem and must be considered 
a critical structure when planning radiotherapy. The 
occurrence of dysphagia is related to both tumour 
localisation and the advancement of the disease. 
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